Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.